Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 53 of 55 for:    hki-272 OR neratinib

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02977780
Recruitment Status : Recruiting
First Posted : November 30, 2016
Last Update Posted : February 28, 2018
Sponsor:
Collaborators:
Eli Lilly and Company
Celgene
Puma Biotechnology, Inc.
Accelerate Brain Cancer Cure
Information provided by (Responsible Party):
Brian Alexander, MD, Dana-Farber Cancer Institute

Tracking Information
First Submitted Date  ICMJE November 18, 2016
First Posted Date  ICMJE November 30, 2016
Last Update Posted Date February 28, 2018
Actual Study Start Date  ICMJE February 9, 2017
Estimated Primary Completion Date May 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 29, 2016)
Overall Survival in Experimental Arms Compared with Standard Therapy [ Time Frame: 2 years ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02977780 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 29, 2016)
  • Incidence of Treatment-Emergent Adverse Events [ Time Frame: 2 years ]
    Safety will be assessed by quantifying the toxicities and grades experienced by subjects, including serious adverse events (SAEs). The following will also be measured as part of safety: laboratory safety assessments, KPS status, vital signs and physical examinations.
  • Progression Free Survival Among Experimental Arms And Biomarker Groups [ Time Frame: 2 years ]
  • Overall Survival Among Experimental Arms And Biomarker Groups [ Time Frame: 2 years ]
  • Association Between Progression Free Survival and Overall Survival Effects Of Experimental Agents [ Time Frame: 2 years ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Official Title  ICMJE INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Brief Summary

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).

The drugs involved in this study are :

  • Abemaciclib
  • Temozolomide (temodar)
  • Neratinib
  • CC115
Detailed Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the study drug works in treating a specific disease. "Investigational" means that the drug is being studied.

In this research study, the investigators are looking to compare the effects, good and bad, of the standard of care with the three investigational agent sub-studies Abemaciclib, Neratinib, CC115 to help people with Glioblastoma including the specific molecular changes in the genes and proteins.

The FDA has approved Temozolomide (temodar) as a treatment for this disease, however the FDA has not approved Abemaciclib, CC115, Neratinib for any diseases.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Glioblastoma
Intervention  ICMJE
  • Drug: Temozolomide
    Temzolomide capsules
    Other Name: Temodar
  • Drug: Neratinib
    Neratinib tablets
  • Drug: CC-115
    CC-115 capsule
    Other Name: CC0483115
  • Drug: Abemaciclib
    Abemaciclib capsules
    Other Name: LY2835219
Study Arms  ICMJE
  • Active Comparator: Temozolomide
    • Daily Radiation for a maximum of 49 days.
    • Temozolomide will be administered orally on a daily dosing schedule
    • Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
    • Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)
    Intervention: Drug: Temozolomide
  • Experimental: Abemaciclib with Temozolomide
    • Daily Radiation for a maximum of 49 days.
    • Temozolomide will be administered orally on a daily dosing schedule during radiation
    • Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
    • Abemaciclib will be taken post radiation at a twice daily oral pre-determined dose
    Interventions:
    • Drug: Temozolomide
    • Drug: Abemaciclib
  • Experimental: CC-115
    • Twice daily oral dosing of CC-115
    • Daily Radiation for a maximum of 49 days
    • CC115 will also be taken twice daily post radiation
    Intervention: Drug: CC-115
  • Experimental: Neratinib with Temozolomide
    • Daily Radiation for a maximum of 49 days.
    • Temozolomide will be administered orally on a daily dosing schedule
    • Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
    • Neratinib will be taken post radiation at a daily oral pre-determine dose
    Interventions:
    • Drug: Temozolomide
    • Drug: Neratinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 29, 2016)
280
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 2021
Estimated Primary Completion Date May 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants must have histologically confirmed intracranial glioblastoma or gliosarcoma following maximum surgical resection. Tumors primarily localized in the infratentorial compartment will be excluded.
  • Participants may have had prior surgery for glioblastoma or gliosarcoma but no systemic or radiation therapy.
  • Age ≥ 18 years.
  • Karnofsky performance status ≥60
  • Participants must have normal organ and marrow function as defined below:

    • Leukocytes ≥3,000/mL
    • Absolute neutrophil count ≥1,500/mL
    • Platelets ≥100,000/mL
    • Hemoglobin ≥ 9g/dl
    • Total bilirubin within normal institutional limits (except for participant's with Gilbert's disease)
    • AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
    • Creatinine ≤ institutional upper limit of normal OR
    • Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
    • Potassium within normal institutional range, or correctable with supplements
    • Serum amylase ≤ 1.5 x institutional upper limit of normal
    • Serum lipase ≤ 1.5 x institutional upper limit of normal
    • INR < 2.0
    • PTT ≤ institutional upper limit of normal, unless receiving therapeutic low molecular weight heparin
  • Must be able to swallow pills.
  • Participants must plan to begin radiation therapy 14-42 days after surgical resection.
  • Immunohistochemically negative for IDH1 R132H mutation.
  • Evidence that the tumor MGMT promoter is unmethylated by standard of care assays.
  • Genotyping data available or in process (data must be available at time of initial registration if randomization probabilities differ across biomarker subgroups as determined by the DFCI Coordinating Center) to assign biomarker subgroups through whole exome sequencing, whole genome copy number analysis, or a combination as described in Section 9.1.
  • MRI with gadolinium should be obtained within 21 days prior to beginning treatment. Patients without measurable disease are eligible. Participants must be able to undergo MRIs (CTs are not allowed for response assessment on study).
  • The effects of the experimental agents used in this study on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential (women who are not free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation unless otherwise specified in sub-study that the participant is randomized to. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • For women of child bearing potential (women who are not free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) a negative serum pregnancy test must be documented prior to initial registration.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants will not be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis revealed glioblastoma.
  • Planned major surgery.
  • Participants who are receiving any other investigational agents.
  • Participants who have had any prior cranial radiotherapy.
  • Planned use of Optune™.
  • History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, and/or (b) malignancy was cervical cancer in situ, superficial bladder cancer or basal cell or squamous cell carcinoma of the skin, and malignancy has been treated. Patients who meet the above listed criteria and are only on preventative treatment will be deemed eligible.
  • History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician.
  • Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
  • Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia.
  • Known history of congenital QT prolongation or Torsade de pointes (TdP).
  • Complete left bundle branch or bifascicular block.

    --QTc interval > 450 ms for men or > 470 ms for women.

  • Persistent or history of clinically meaningful ventricular arrhythmias or atrial fibrillation.
  • Unstable pectoris or myocardial infarction ≤ 3 months prior to starting study treatment.
  • Uncontrolled hypertension (blood pressure ≥ 160/95 mmHg).
  • Other clinically significant heart disease such as congestive heart failure requiring treatment.
  • Uncontrolled diabetes mellitus, or subjects with either of the following:
  • Fasting blood glucose (FBG defined as fasting for at least 8 hours) ≥ 200 mg/dL (7.0 mmol/L), or
  • HbA1c ≥ 8%
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, chronic liver disease (e.g., cirrhosis, hepatitis), chronic renal disease, pancreatitis, chronic pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements. Subjects must be free of any clinically relevant disease (other than glioma) that would, in the treating investigator's opinion, interfere with the conduct of the study or study evaluations.
  • Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNS [qualitative] is detected).
  • Known acute or chronic pancreatitis.
  • Participants with active diarrhea ≥ CTCAE grade 2 despite medical management.
  • Active infection requiring antibiotics.
  • Pregnant or breastfeeding.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or extensive small bowel resection). Participants with unresolved diarrhea ≥ CTCAE grade 2 will be excluded as previously indicated.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in study.
  • Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participant must be off any EIAEDs for at least 7 days prior to planned start of study treatment. A list of EIAED and other inducers of CYP3A4 is provided. Among non-EIAED, caution is recommended with use of valproic acid due to potential for drug interaction.
  • Participants taking a drug known to be strong inhibitors or inducers of isoenzyme CYP3A. Participant must be off CYP3A inhibitors and inducers for at least 7 days prior to planned start of study treatment. NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to planned start of study treatment and during the entire study treatment period due to potential CYP3A4 interaction.
  • Current use of herbal preparations/medications, including but not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, ginseng. Participants should stop using these herbal medications 7 days prior to planned start of study treatment.
  • Current use of warfarin sodium or any other coumadin-derivative anticoagulant. Participant must be off Coumadin-derivative anticoagulants for at least 7 days prior to planned start of study treatment. Low molecular weight heparin and factor Xa inhibitors are allowed.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Brian Alexander, MD MPH 617-732-7560 Brian_Alexander@dfci.harvard.edu
Contact: Sarah Gaffey 617-632-4341 sarah_gaffey@dfci.harvard.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02977780
Other Study ID Numbers  ICMJE 16-443
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Brian Alexander, MD, Dana-Farber Cancer Institute
Study Sponsor  ICMJE Dana-Farber Cancer Institute
Collaborators  ICMJE
  • Eli Lilly and Company
  • Celgene
  • Puma Biotechnology, Inc.
  • Accelerate Brain Cancer Cure
Investigators  ICMJE
Principal Investigator: Brian Alexander, MD MPH Dana-Farber Cancer Institute
PRS Account Dana-Farber Cancer Institute
Verification Date February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP